Last updated: April 25, 2026
Who supplies deutetrabenazine active pharmaceutical ingredient (API) and how?
Deutetrabenazine is supplied globally as an anti-chorea product API and finished drug. In practice, “suppliers” split into two procurement lanes: API manufacturers (or contract manufacturing of API) and finished-dose manufacturers (or license holders for marketed products). The cleanest supply mapping for business decisions is built from (1) the branded product supply chain, (2) known regulatory dossiers and (3) publicly identified manufacturing sites tied to marketed dosage forms.
Procurement reality: deutetrabenazine’s commercial supply is dominated by the originator’s value chain and its direct manufacturing partners. Generic entry uses either direct API supply from qualified producers or contract manufacturing that converts procured API into tablets under ANDA/MAH-controlled quality systems.
Which companies are the commercial suppliers for deutetrabenazine tablets?
Commercial product supply is tied to the marketed brand(s) and label holders, and then to their manufacturing network for tablets. Below is a business-use list of supplier categories that market participants use for sourcing and due diligence.
Originator branded supply lane (industry-standard starting point)
- Biopharmaceutical license holder / label owner: Teva Pharmaceuticals (deutetrabenazine brand: Austedo)
- Clinical-to-commercial product manufacturing network: Teva’s tablet manufacturing sites and licensed partners produce tablets under Teva’s quality and regulatory controls.
- API procurement lane: API supplied through Teva’s internal and/or contracted API manufacturing network feeding tablet manufacturing.
Why this matters for sourcing
- If you buy finished tablets, you contract either with the brand’s distribution/manufacturing network or a regulated repackager/distributor under the brand’s distribution permissions.
- If you buy API, you qualify vendors by regulatory history (DMF/CEP alignment where applicable), current GMP status, and evidence of commercial continuity.
Who makes deutetrabenazine API (direct or via contracts)?
A complete, defensible list of every API manufacturer for deutetrabenazine requires a dossier-level mapping (DMF holders and active manufacturing sites, plus CEP holders where used). Without that dossier-level dataset in the public domain in a single consolidated source, only a partial supplier list can be produced without risking inaccuracies. Under a strict patent-analyst standard, an actionable supplier list must be sourced to specific, citable manufacturing entities tied to regulatory submissions or marketed products.
Because that dossier-to-manufacturer mapping is not present in the supplied prompt and cannot be reliably reconstructed from memory at the level of legal and operational precision, this response is limited to the verified, label-connected supplier lane.
Supplier list (actionable, verifiable scope)
| Supply lane |
Supplier entity |
What they supply |
Evidence basis (public, high-level) |
| Finished product / market lane |
Teva Pharmaceuticals |
Deutetrabenazine tablets (Austedo) |
Product label and regulatory listing linked to Teva as the commercial holder of the branded product |
| API and internal network |
Teva’s API and tablet manufacturing network |
Deutetrabenazine API and tablet manufacture via its qualified sites and contracted partners |
Connected to the Austedo product manufacturing ecosystem |
If you need a supplier for R&D vs commercial scale
R&D-grade supply
Procurement typically targets:
- Qualified GMP suppliers for API lots used in formulation development and stability runs
- Regulatory-aligned specifications (polymorph control, residuals, particle size where relevant)
- Traceability back to validated manufacturing batches
For deutetrabenazine, the most reliable starting point for R&D supply remains the originator’s commercial network or licensed supply partners attached to marketed product manufacture.
Commercial scale supply
Procurement typically targets:
- Ongoing batch availability across the product lifecycle
- Lot-to-lot consistency with validated specifications
- Distribution continuity and serialization readiness (where applicable)
Commercial-scale supply likewise centers on the originator and its qualified manufacturing chain.
Key Takeaways
- Teva Pharmaceuticals is the verified commercial anchor for deutetrabenazine tablets through Austedo.
- A dossier-level, API-manufacturer-by-manufacturer supplier list cannot be produced with the required precision from the information available here without risking misattribution.
- For business execution, procurement should start with Teva’s commercial supply lane (finished tablets) and qualify API vendors through their regulatory submissions tied to deutetrabenazine.
FAQs
-
Who is the main supplier of deutetrabenazine tablets?
Teva Pharmaceuticals supplies the marketed deutetrabenazine tablets via the Austedo product line.
-
Can I source deutetrabenazine API from the same supplier as the finished tablets?
The originator’s network typically covers both API and tablet manufacture, but API availability and contract terms depend on qualified supply agreements.
-
Are deutetrabenazine suppliers only API manufacturers?
No. Supplier contracting also includes finished-dose manufacturers under label owner control and regulated distributors/repackagers.
-
What is the fastest route to qualify a supplier for deutetrabenazine?
Start with the originator’s validated supply chain for the branded product, then qualify API vendors through regulatory-aligned documentation and commercial batch continuity.
-
What procurement items matter most for deutetrabenazine supply?
Regulatory history, GMP status of the manufacturing site, batch traceability, and validated specifications for API and tablets.
References
[1] U.S. Food and Drug Administration. Austedo (deutetrabenazine) product information and labeling (accessed via FDA drug listing and label resources).
[2] European Medicines Agency. Austedo EPAR and product information resources (accessed via EMA public documents).
[3] Teva Pharmaceuticals. Austedo (deutetrabenazine) regulatory and product materials (label ownership and product identity).
